Heterotopic heart transplantation: where do we stand?

被引:10
|
作者
Flecher, Erwan [1 ]
Fouquet, Olivier [2 ]
Ruggieri, Vito Giovanni [1 ]
Chabanne, Celine [1 ]
Lelong, Bernard [1 ]
Leguerrier, Alain [1 ]
机构
[1] Rennes Univ Hosp, Dept Cardiothorac & Vasc Surg, Rennes, France
[2] Angers Univ Hosp, Dept Cardiac Surg, Angers, France
关键词
Heterotopic; Orthotopic; Transplantation; FIXED PULMONARY-HYPERTENSION; CIRCULATORY SUPPORT; HEMODYNAMICS; PIONEER;
D O I
10.1093/ejcts/ezt136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orthotopic heart transplantation (OHT) is a well established and commonly utilized procedure for end-stage heart failure patients. Heterotopic heart transplantation (HHT) is a surgical procedure that allows the graft to be connected to the native heart in a parallel fashion. The main advantage of HHT is to assist the patient's native heart and to maintain circulation in the cases of severe acute rejection. HHT has also been proposed to overcome pulmonary hypertension, to increase the size of the donor pool and to decrease waiting times without increasing morbidity caused by the procedure. However, only a few papers have reported the short- or long-term results of HHT, and most of these studies have included <30 cases. OHT remains the standard technique and is preferable whenever the patient meets the current criteria and a suitable organ is available. HHT is far less useful than in the past because of the major advances in immunosuppression therapy and the development of long-term mechanical circulatory support. This study reviews the origin of HHT and discusses clinical developments, including their advantages and disadvantages.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [41] Gene Therapy for Heart Failure: Where Do We Stand?
    Naim, Charbel
    Yerevanian, Armen
    Hajjar, Roger J.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (02)
  • [42] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [43] History of pediatric liver transplantation. Where are we coming from? Where do we stand?
    Otte, JB
    PEDIATRIC TRANSPLANTATION, 2002, 6 (05) : 378 - 387
  • [44] Transplantation tolerance: the big picture. Where do we stand, where should we go?
    Waldmann, H.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 189 (02): : 135 - 137
  • [45] Kidney transplantation from living donors : where do we stand ?
    Bitker, M. O.
    Barrou, B.
    Van Gla-Beke, E.
    Chatelain, Ch.
    Richard, F.
    E-MEMOIRES DE L ACADEMIE NATIONALE DE CHIRURGIE, 2005, 4 (01): : 14 - 18
  • [46] Hepatitis C virus and liver transplantation: where do we stand?
    Burra, Patrizia
    De Martin, Eleonora
    Zanetto, Alberto
    Senzolo, Marco
    Russo, Francesco Paolo
    Zanus, Giacomo
    Fagiuoli, Stefano
    TRANSPLANT INTERNATIONAL, 2016, 29 (02) : 135 - 152
  • [47] Pediatric liver transplantation in Latin America: Where do we stand?
    Feier, Flavia
    Antunes, Eduardo
    D'Agostino, Daniel
    Varela-Fascinetto, Gustavo
    Jarufe, Nicolas
    Patillo, Juan C.
    Vera, Alonso
    Carrasco, Felix
    Kondo, Mario
    Porta, Gilda
    Chapchap, Paulo
    Seda-Neto, Joao
    PEDIATRIC TRANSPLANTATION, 2016, 20 (03) : 408 - 416
  • [48] Epilepsy: Where do we stand? Where are we headed?
    Elger, C. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 8 - 8
  • [49] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    Skeletal Muscle, 1
  • [50] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    SKELETAL MUSCLE, 2011, 1